The pharmacokinetics and metabolism of mitoxantrone in man
Authors:
- 1 June 1985
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 3 (2) , 109-116
Abstract
An HPLC method using paired-ion chromatography on RP C-18 material was developed. After sample clean up on XAD columns, mitoxantrone (Novantrone®; dihydroxyanthracenedione) in concentrations below 1 ng/ml in serum and 0.2 ng/ml in urine were measurable with a coefficient of variation <9.3% at a wavelength of 658 nm. Four metabolites were separated in urine. The major metabolite cochromatographed with the synthesized dicarboxylic acid of mitoxantrone. Within 48 hours 4.4% of the administered dose was excreted in urine as mitoxantrone, 0.5% as metabolite 1 and 0.3% as metabolite 2. The pharmacokinetic parameters are adequately described by a three-compartment model with a terminal half-life of 214.8 hours, and a volume of distribution (ss) of 3792 litres. The total body clearance was 358 ml/min and the renal clearance was 26.2 ml/min.Keywords
This publication has 14 references indexed in Scilit:
- Mitoxantrone and cyclophosphamide in patients with advanced breast cancer.1984
- Mitoxantrone: An active new agent in the treatment of advanced breast cancerCancer Chemotherapy and Pharmacology, 1984
- Mitoxantrone metabolism in the isolated perfused rat liverCancer Chemotherapy and Pharmacology, 1984
- Disposition of mitoxantrone in patientsCancer Treatment Reviews, 1983
- Therapeutic activity of mitoxantrone and ametantrone against murine tumorsCancer Treatment Reviews, 1983
- Mitoxantrone hydrochloride (NSC-310739) in lymphomaInvestigational New Drugs, 1983
- Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantroneJournal of Chromatography B: Biomedical Sciences and Applications, 1982
- Clinical kinetics of 1,4-dihydroxy-5,8-bis [[2- [(2-hydroxyethyl)amino ]ethyl] amino]-9,10-anthracenedioneClinical Pharmacology & Therapeutics, 1982
- Clinical analysis for the anti-neoplastic agent 1,4-dihydroxy-5,8-bis{{2-[(2-hydroxyethyl)amino]ethyl}amino} 9,10-anthracenedione dihydrochloride (NSC 301739) in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1981
- An HPLC Method for the Quantitative Determination of 1,4-Dihydroxy-5,8 Bis [[2-[(2-Hydroxyethyl) Amino] Ethyl] Amino] 9,10 - Anthracenedione (DHAQ, Lederle Labs CL232 315, NCS 301739) in SerumJournal of Liquid Chromatography, 1980